Phase II study of multiple doses of GTx 758 (1800, 3000 or 4500 mg/day) on testosterone levels and pharmacokinetics in male volunteers
Phase of Trial: Phase II
Latest Information Update: 14 Dec 2010
At a glance
- Drugs GTx 758 (Primary)
- Indications Prostate cancer
- Focus Biomarker; Pharmacodynamics; Pharmacokinetics
- 14 Dec 2010 Results were presented at the Annual Meeting of the Society of Urologic Oncology 2010, according to a GTx media release.
- 15 Sep 2010 Top-line results have been reported in a GTx media release. Full results from this trial will be presented at upcoming medical meetings.
- 15 Sep 2010 Status changed from active, no longer recruiting to completed based on results reported in a GTx media release.